Cambridge Healthtech Institute’s 5th Annual

Novel Antibody Constructs and Alternative Scaffolds
5-6 November 2014


In-depth research with the industry reveals the emergence of a wide range of exciting and innovative technologies with a variety of applications. In Europe there is a strong focus on platforms for bi-specific products, and on unique constructs and scaffolds, particularly on Fc engineering. This conference will present platforms for novel biotherapeutics with improved features such as enhanced access to the target site and better binding, and unique modes of action such as immune and complement activation. Presentations will cover target selection, and drug and platform discovery and development, and include challenges overcome and evidence for efficacy.


Topics will include, but are not limited to, the following: 


1. Creative engineering and novel applications of bi-specific technology.  For example: Interesting and effective combinations of targets; rationale behind the choice of targets; bi-specifics that engage T cells.

2. Fc engineering approaches and the impact on complement activation, binding, cross linkage, half-life and effector function.  For example: Fc silencing; application of Fc engineering for Immune control; impact of Fc glycosylation / non-glycosylation; Fc receptor based affinity chromatography.

3. Unique platforms for creative engineering of scaffolds and constructs 

4. Technologies for targets and lead selection.  For example: Affinity engineering to select targets; selection for good synergy between targets and affinity; lead selection and optimization; rational design of antibodies

5. Innovative engineering for difficult to reach targets, special delivery and/or sustained release 

6. Unique Modes of Action together with evidence of effectiveness 

7. Unique antibody mixture platforms for combined treatment 

8. Applications such as neurological disorders, inflammation and infection, immune, allergic and autoimmune disorders 

9. T cell redirection approaches including immunotherapy, and CD3 targeting 

 

 

If you would like to submit a proposal to give a presentation at this meeting, please click here.


Deadline for submission is 21 March 2014 


All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships. 


 

For more details on the conference, please contact: 

Nicole Lyscom, Ph.D.
Conference Director
Cambridge Healthtech Institute
Tel: +44 7791 866489
Email: nlyscom@healthtech.com 

 

For exhibit & sponsorship opportunities, please contact: 

Carol Dinerstein
Director, Business Development
Cambridge Healthtech Institute
Tel: 1 781-972-5471
Email: dinerstein@healthtech.com